Thursday, November 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 19, 2026

SEC proposes exemption for tokenizing stocks. What could go wrong?

View original at finance.yahoo.com
SEC proposes exemption for tokenizing stocks. What could go wrong? Scott Melker discusses the US Securities and Exchange Commission's (SEC) proposed innovation exemption for tokenizing securities without the issuer's permission, using Apple (AAPL) stock as an example…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • ETFs do not require issuer approval to include a security, and the SEC is using this as precedent for its proposed innovation exemption.

    60% confidence
  • Unauthorized tokenization creates infinite synthetic supply risk: anyone can mint Apple tokens, 10 different platforms could each have their own Apple token with no official connection to Apple, collapsing price discovery with no single source of truth.

    60% confidence
  • Unauthorized tokenization of stocks in DeFi will be very stinky and could get very ugly, given that DeFi has proven not entirely secure when AI and hacks are factored in.

    60% confidence
  • Tokenized stocks will enable 24/7 365-day-a-year global trading on blockchain rails, largely on unregulated decentralized exchanges without KYC/AML, accessible to everyone worldwide, and usable as DeFi collateral.

    60% confidence
  • The DTCC, which settles 4.7 quadrillion in securities volume per year, is moving to blockchain rails after receiving a no-action letter from the SEC.

    60% confidence
  • Under issuerless tokenization, accountability is absent: Apple did not issue the token, and the tokenization platform claims no liability.

    60% confidence
  • A corporate action such as a stock split, buyback, dividend, or M&A not reflected in tokenized stock can cause a depeg event where the token and real stock trade at different prices, potentially leading to cascading liquidations and weekend contagion into real equity markets on Monday open.

    60% confidence
  • The SEC is proposing an innovation exemption that would allow tokenization of stocks without permission from the issuer, potentially by end of the week.

    60% confidence
  • The core legal question of tokenization is whether it creates a new security or is merely a new technological wrapper around an existing security.

    60% confidence
  • If third parties can tokenize Apple or Amazon without the issuer at the table, there is no theoretical limit on how many wrappers of the same company can exist at once.

    60% confidence
  • By end of 2026 everything would be trading on blockchain rails under Project Crypto.

    60% confidence
  • Unauthorized tokenization turns every public company into a potential Terra Luna, with the contagion path running through DeFi lending markets and back into real equity prices, and nobody has a legal duty to make holders whole.

    60% confidence
  • Securitize advocates for one issuer at the table, one canonical token, one source of truth, and one legally accountable entity — warning that without this the system may be designed to systematically detonate.

    60% confidence
  • Stocks already trade freely in secondary markets, derivatives exist, and ETFs exist — all providing existing precedent that issuer permission may not be legally required for tokenization wrappers.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com